Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 6/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19505804 | 1.00 | KMT2A (0.44) | KMT2AMMP2ANPEPMEN1ALDH1A1 | |
| SCHEMBL19506184 | 0.91 | CA12 (0.35) | KMT2AMMP2ANPEPMEN1ALDH1A1 | |
| SCHEMBL19475623 | 0.88 | ELOVL6 (0.36) | KMT2AGAA | |
| SCHEMBL19506085 | 0.85 | ALDH1A1 (0.35) | KMT2AMMP2ANPEPALDH1A1PDK2 | |
| SCHEMBL19506186 | 0.84 | PKM (0.43) | KMT2AMMP2ANPEPALDH1A1POLB | |
| SCHEMBL14672225 | 0.82 | NR1H2 (0.39) | KMT2AMMP2ANPEPMEN1 | |
| SCHEMBL14663320 | 0.82 | NR1H2 (0.39) | KMT2AMMP2ANPEPMEN1 | |
| SCHEMBL30181072 | 0.82 | NR1H2 (0.39) | KMT2AMMP2ANPEPMEN1 | |
| SCHEMBL19505789 | 0.79 | GRM5 (0.32) | KMT2AMEN1 | |
| SCHEMBL19506080 | 0.78 | KMT2A (0.33) | KMT2AMMP2ANPEPMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | CCL11, MAN2A1, PREP | KMT2A 1988/4885MMP2 338/4885ANPEP 217/4885 |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | MASP2, MAN2A1, CCL11 | KMT2A 2088/4885MMP2 314/4885ANPEP 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.